Search research articles
Contact Us
Filters
Showing results (271-280 of 311) with videos related to
Page
of 32
Sort By:
The New England Journal of Medicine
|
October 26, 2007
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer
Jan B Vermorken, Eva Remenar, Carla van Herpen, et al.
Targeted Oncology
|
November 19, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
Céleste Lebbé, Antoine Italiano, Nadine Houédé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2017
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies
Philippe Aftimos, Christian Rolfo, Sylvie Rottey, et al.
Frontiers in Immunology
|
November 23, 2017
Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer
Cinzia Solinas, Soizic Garaud, Pushpamali De Silva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2021
Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors
James Spicer, Aurélien Marabelle, Jean-Francois Baurain, et al.
Acta Oncologica (Stockholm, Sweden)
|
August 22, 2020
Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel
Giacomo Bregni, Tiberio Sticca, Silvia Camera, et al.
Breast Cancer Research and Treatment
|
March 20, 2016
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors
Steven A Limentani, Mario Campone, Thierry Dorval, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 5, 2013
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer
José Baselga, Patricia Gómez, Richard Greil, et al.
Breast Cancer Research and Treatment
|
April 9, 2024
Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium
Mariana Brandão, Diogo Martins-Branco, Claudia De Angelis, et al.
Molecular Cancer Therapeutics
|
October 18, 2019
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
Franck Morschhauser, Jean-Pascal Machiels, Gilles Salles, et al.
Page
of 32
Search research articles
Search
Showing results (271-280 of 311) with videos related to
Sort By:
Page
of 32
The New England Journal of Medicine
|
October 26, 2007
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer
Jan B Vermorken, Eva Remenar, Carla van Herpen, et al.
Targeted Oncology
|
November 19, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
Céleste Lebbé, Antoine Italiano, Nadine Houédé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2017
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies
Philippe Aftimos, Christian Rolfo, Sylvie Rottey, et al.
Frontiers in Immunology
|
November 23, 2017
Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer
Cinzia Solinas, Soizic Garaud, Pushpamali De Silva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2021
Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors
James Spicer, Aurélien Marabelle, Jean-Francois Baurain, et al.
Acta Oncologica (Stockholm, Sweden)
|
August 22, 2020
Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel
Giacomo Bregni, Tiberio Sticca, Silvia Camera, et al.
Breast Cancer Research and Treatment
|
March 20, 2016
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors
Steven A Limentani, Mario Campone, Thierry Dorval, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 5, 2013
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer
José Baselga, Patricia Gómez, Richard Greil, et al.
Breast Cancer Research and Treatment
|
April 9, 2024
Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium
Mariana Brandão, Diogo Martins-Branco, Claudia De Angelis, et al.
Molecular Cancer Therapeutics
|
October 18, 2019
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
Franck Morschhauser, Jean-Pascal Machiels, Gilles Salles, et al.
Page
of 32